down arrow

Reneo Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US75974E1038
USD
3.11
0.17 (5.78%)

Dec 18

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

2.973.12

52 Week

1.709.40
Valuation
Technical
Day's Volume

CASH

4.62 k

Shareholding (Mar 2025)

FII

6.93%

Held by 28 FIIs

DII

60.39%

Held by 12 DIIs

Promoter

22.55%

How big is Reneo Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Reneo Pharmaceuticals, Inc. has a market capitalization of 30.62 million, with net sales of 0.00 million and a net profit of -60.17 million for the latest four quarters. As of December 2024, the company reported shareholder's funds of 103.83 million and total assets of 114.91 million.

Market Cap: As of Jun 18, Reneo Pharmaceuticals, Inc. has a market capitalization of 30.62 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters ending in March 2025, December 2024, September 2024, and June 2024, Reneo Pharmaceuticals reported net sales of 0.00 million and a net profit of -60.17 million.<BR><BR>Balance Sheet Snapshot: As of December 2024, the company reported shareholder's funds of 103.83 million and total assets of 114.91 million.

Read More

What does Reneo Pharmaceuticals, Inc. do?

22-Jun-2025

Reneo Pharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $16 million and a market cap of $30.62 million. Key metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -66.39%.

Overview: <BR>Reneo Pharmaceuticals, Inc. operates within the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -16 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 30.62 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.06 <BR>Return on Equity: -66.39% <BR>Price to Book: 0.34<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Reneo Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of September 4, 2025, Reneo Pharmaceuticals shows a mildly bearish trend with mixed technical indicators and has significantly underperformed the S&P 500, with year-to-date and one-year returns of -71.16% and -83.47%, respectively.

As of 4 September 2025, the technical trend for Reneo Pharmaceuticals, Inc. has changed from sideways to mildly bearish. The daily moving averages indicate a mildly bearish stance, while the weekly MACD and KST are mildly bullish, suggesting some conflicting signals. The Bollinger Bands show a bullish weekly trend but a bearish monthly trend. Overall, the indicators reflect a mixed technical picture, leaning towards bearish in the short term.<BR><BR>In terms of performance, Reneo Pharmaceuticals has significantly underperformed compared to the S&P 500, with a year-to-date return of -71.16% versus the S&P 500's 12.22%, and a one-year return of -83.47% compared to 17.14% for the benchmark.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 35 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.06

stock-summary
Return on Equity

-89.82%

stock-summary
Price to Book

0.45

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-15 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
25.4%
0%
25.4%
6 Months
28.51%
0%
28.51%
1 Year
-63.88%
0%
-63.88%
2 Years
-78.25%
0%
-78.25%
3 Years
38.22%
0%
38.22%
4 Years
-95.51%
0%
-95.51%
5 Years
0%
0%
0.0%

Reneo Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-255.72%
EBIT to Interest (avg)
-41.19
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.06
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.40
EV to EBIT
0.91
EV to EBITDA
0.92
EV to Capital Employed
10.92
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
1196.18%
ROE (Latest)
-66.39%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bullish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 20 Schemes (10.13%)

Foreign Institutions

Held by 28 Foreign Institutions (6.93%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -185.19% vs 72.31% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-16.10",
          "val2": "-6.40",
          "chgp": "-151.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-15.40",
          "val2": "-5.40",
          "chgp": "-185.19%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -49.29% vs 32.12% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-53.50",
          "val2": "-36.40",
          "chgp": "-46.98%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-52.70",
          "val2": "-35.30",
          "chgp": "-49.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-16.10
-6.40
-151.56%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-15.40
-5.40
-185.19%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -185.19% vs 72.31% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-53.50
-36.40
-46.98%
Interest
0.10
0.00
Exceptional Items
0.10
0.00
Consolidate Net Profit
-52.70
-35.30
-49.29%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -49.29% vs 32.12% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Reneo Pharmaceuticals, Inc. stock-summary
stock-summary
Reneo Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."